Moreover, it has been reported that AURKA drives the evolution of resistance to EGFR inhibitors in lung cancer [31], and the aberrant activation of AURKA contributes to the highly aggressive nature of lymphoproliferative disorders [32]. This evidence concerns the gene EGFR and lung carcinoma.